Cash Payment(s). A lump sum payment calculated as provided below:

Cash Payment. Prior to any public announcement or disclosure by Neurocrine, and in any event, within [†] days after IND Acceptance, Neurocrine shall notify Xenon in writing if a [[Unknown Identifier]] Product achieves IND Acceptance in either [[Unknown Identifier]] or a Major Indication, whichever occurs first. After the receipt of such notice from Neurocrine, Xenon shall submit to Neurocrine an invoice for a payment of # if the IND Acceptance is for SCN8A-EE, eleven million two hundred fifty thousand Dollars ($11,250,000) or # if the IND Acceptance is for a Major Indication, four million five hundred thousand Dollars ($4,500,000). Neurocrine shall pay such amount to Xenon within [†] days after the receipt of such invoice. For clarity, Neurocrine will pay either the amount in the preceding clause (i) or the amount in the preceding clause (ii) (if any), depending on which IND achieves IND Acceptance first, but not both amounts, except as set forth in [Section 8.3(c)].

Cash Payment(s). Continuation of such employee’s monthly Base Salary for the Severance Period indicated below (the “Severance Period”), based upon his or her title/role; provided that if the Covered Employee commences new employment such severance payments shall end when the new employment begins.

Cash Payment. A lump sum cash payment equal to fifty-two (52) weeks of Executive’s salary as of the date on which Executive’s separation from service occurs, payable as provided in Section 6(b). The lump sum cash payment will be considered wages allocated equally to each of the weeks covered by the payment for purposes of any applicable unemployment compensation or workers compensation laws, and any applicable disability insurance program, but will not be considered to extend Executive’s employment beyond the date of Executive’s separation from service under any Company qualified retirement plan or other Company benefit plan or program.

Cash Payment. The Company will pay you the equivalent of four (4) months of your base salary in effect as of the Separation Date, subject to standard payroll deductions and withholdings (“Cash Payment”). This Cash Payment will be paid in a lump sum on the first regular payday no earlier than one week after the later of # the Effective Date (as defined below) or # the Separation Date.

Cash Payment. Neurocrine shall pay to Xenon a one-time upfront payment of thirty million Dollars ($30,000,000) within ten (10) business days after the Effective Date.

Estimated Cash Payment. Seller Representative has delivered to Buyer # a certificate signed by the Seller Representative setting forth Sellers’ best estimate of the Debt Amount, Transaction Expenses Balance, Working Capital as of the Closing Date, the Working Capital Deficit, if any, the Representative Expense Fund Amount in each case as of the Closing Date and, based on such estimates, a calculation of the Cash Payment (the “Estimated Cash Payment”) and # all records and work papers necessary to compute and verify the information set forth in such certificate.

Cash Payment. Upon the earliest to occur of: # the undersigned’s death or disability (as defined in Treasury Regulation Section 1.409A-3(i)(4)(i)(A)) or # the consummation of a Covered Transaction (provided that such Covered Transaction constitutes a “change in the ownership or effective control” of the Company or a “change in the ownership of a substantial portion of the assets” of the Company, in each case within the meaning of Code [Section 409A] and the regulations promulgated thereunder), or # the completion of the Performance Period, the vested portion of such Award, if any, shall be paid in cash following the date of such death, disability, Covered Transaction, or the completion of the Performance Period, subject to the undersigned executing a restrictive covenant agreement (containing nonsolicitation, nondisparagement and nondisclosure provisions) which includes a general release of claims in favor of the Company (such agreement, the “Release”) within sixty (60) days following the date of such death, disability, Covered Transaction or the completion of the Performance Period, with payment to be made within five (5) business days after the date the Release becomes non-revocable; provided, however, that if such sixty (60) day period spans two calendar years, payment shall be made in the second calendar year, regardless of when the Release becomes non-revocable (the date on which such payment is made, the “Payment Date”); provided, further, that if the undersigned is terminated for Cause prior to the Payment Date, the entire Award shall be immediately forfeited with no compensation due to the undersigned (including, without limitation, if at any time following the undersigned’s termination of Continuous Service and prior to the Payment Date, the Board determines that grounds to terminate the undersigned’s Continuous Service for Cause existed at the time of such termination). For the avoidance of doubt, if the Release does not become non-revocable within sixty (60) days following the date of such death, disability, Covered Transaction or the completion of the Performance Period, no Cash Retention Bonus shall be payable.

Upfront Cash Payment. Licensee shall pay [[AstraZeneca:Organization]] a non-refundable and non-creditable upfront amount in cash equal to $5,000,000. On the Effective Date, [[AstraZeneca:Organization]] shall provide an invoice to Licensee for the upfront cash payment due, which amount shall be payable by Licensee no later than ten days following the Effective Date.

Cash Payment Adjustment. Within five (5) Business Days after the Cash Payment becomes final and binding in accordance with Section 1.5: